RDGL Company Profile and Key Details

Average 10-day trading volume of 947.33 thousand shares is below the 3-month average of 1.53 million, indicating normal recent market interest.

The stock is currently mid-range between its 52-week high and low $0.04 and $0.12. With a market capitalization of about $23.71 million, Vivos Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.71). Key stats such as the average daily volume over the past year has been around 1.56 million shares, volume is running light vs its 52-week average. Headquartered in Kennewick, WA, Vivos Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Michael K. Korenko, the company employs approximately 1 people and listed since September 02, 1998. Vivos Inc. is a medical technology company focused on radiation oncology, specializing in the development of internal radiation therapy devices for managing tumors that cannot be surgically removed.

Vivos Inc. trades at a P/E ratio of -6.15, slightly below the S&P 500 average, with a price-to-sales ratio of 239.22 and a price-to-book ratio of 8.55 trading at moderately above to book value. The P/FCF stands at -9.52, also below market averages.

Valuation shows Vivos Inc. trading at a premium to the broader market with a P/E of -6.15.

Our AI price prediction model suggests that Vivos Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Vivos Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.